{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T13:25:18Z","timestamp":1791033918980,"version":"4.1.0"},"reference-count":31,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Fetal hemoglobin (HbF) decreases polymerization of sickle hemoglobin (HbS) and improves outcomes in sickle cell disease (SSD). Therefore, a therapeutic goal in SSD is pharmacologic reactivation of HbF. Silencing of the \u03b3-globin (HbF) gene is associated with DNA methylation. The cytosine analog 5-aza-2\u2032-deoxycytidine (decitabine) hypomethylates DNA by inhibiting DNA methyltransferase. We examined if subcutaneous decitabine could increase HbF levels and improve SSD pathophysiology without cytotoxicity. Eight symptomatic SSD patients resistant or intolerant of standard treatment with hydroxyurea received decitabine 0.2 mg\/kg subcutaneously 1 to 3 times per week in 2 cycles of 6-week duration. Treatment decreased neutrophils and increased mean HbF (6.5% to 20.4%, P &amp;lt; .0001) and mean total hemoglobin (76 to 96 g\/L [7.6 to 9.6 g\/dL], P &amp;lt; .001). Features of vaso-occlusive crisis pathophysiology such as red cell adhesion, endothelial damage, and coagulation pathway activity significantly improved. \u03b3-Globin gene promoter methylation decreased, and platelets and the proportion of megakaryocytes and erythroid cells in the marrow increased without a decrease in marrow cellularity, consistent with a DNA hypomethylating, noncytotoxic mechanism of action. Weekly subcutaneous decitabine produces cumulative increases in HbF and total hemoglobin through a noncytotoxic mechanism of action. Chronic dosing and sustained increases in hemoglobin F and total hemoglobin levels may be possible. Further studies in SSD and thalassemia are indicated.<\/jats:p>","DOI":"10.1182\/blood-2003-05-1738","type":"journal-article","created":{"date-parts":[[2003,8,12]],"date-time":"2003-08-12T02:36:54Z","timestamp":1060655814000},"page":"3865-3870","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":244,"title":["Effects of 5-aza-2\u2032-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease"],"prefix":"10.1182","volume":"102","author":[{"given":"Yogen","family":"Saunthararajah","sequence":"first","affiliation":[{"name":"From the University of Illinois at Chicago (UIC); Medical College of Wisconsin, Milwaukee; The Blood Center of Southeastern Wisconsin, Milwaukee; and Veterans Administration Chicago Health Care System, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl A.","family":"Hillery","sequence":"additional","affiliation":[{"name":"From the University of Illinois at Chicago (UIC); Medical College of Wisconsin, Milwaukee; The Blood Center of Southeastern Wisconsin, Milwaukee; and Veterans Administration Chicago Health Care System, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Lavelle","sequence":"additional","affiliation":[{"name":"From the University of Illinois at Chicago (UIC); Medical College of Wisconsin, Milwaukee; The Blood Center of Southeastern Wisconsin, Milwaukee; and Veterans Administration Chicago Health Care System, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Molokie","sequence":"additional","affiliation":[{"name":"From the University of Illinois at Chicago (UIC); Medical College of Wisconsin, Milwaukee; The Blood Center of Southeastern Wisconsin, Milwaukee; and Veterans Administration Chicago Health Care System, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Dorn","sequence":"additional","affiliation":[{"name":"From the University of Illinois at Chicago (UIC); Medical College of Wisconsin, Milwaukee; The Blood Center of Southeastern Wisconsin, Milwaukee; and Veterans Administration Chicago Health Care System, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Bressler","sequence":"additional","affiliation":[{"name":"From the University of Illinois at Chicago (UIC); Medical College of Wisconsin, Milwaukee; The Blood Center of Southeastern Wisconsin, Milwaukee; and Veterans Administration Chicago Health Care System, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefana","family":"Gavazova","sequence":"additional","affiliation":[{"name":"From the University of Illinois at Chicago (UIC); Medical College of Wisconsin, Milwaukee; The Blood Center of Southeastern Wisconsin, Milwaukee; and Veterans Administration Chicago Health Care System, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsiang","family":"Chen","sequence":"additional","affiliation":[{"name":"From the University of Illinois at Chicago (UIC); Medical College of Wisconsin, Milwaukee; The Blood Center of Southeastern Wisconsin, Milwaukee; and Veterans Administration Chicago Health Care System, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Hoffman","sequence":"additional","affiliation":[{"name":"From the University of Illinois at Chicago (UIC); Medical College of Wisconsin, Milwaukee; The Blood Center of Southeastern Wisconsin, Milwaukee; and Veterans Administration Chicago Health Care System, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"DeSimone","sequence":"additional","affiliation":[{"name":"From the University of Illinois at Chicago (UIC); Medical College of Wisconsin, Milwaukee; The Blood Center of Southeastern Wisconsin, Milwaukee; and Veterans Administration Chicago Health Care System, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021222515440400_REF1","doi-asserted-by":"crossref","unstructured":"Watson J. The significance of the paucity of sickle cells in newborn Negro infants. Am J Med Sci.1948;215: 419-423.","DOI":"10.1097\/00000441-194804000-00008"},{"key":"2020021222515440400_REF2","doi-asserted-by":"crossref","unstructured":"Conley CL, Weatherall DJ, Richardson SN, Shepard MK, Charache S. Hereditary persistence of fetal hemoglobin: a study of 79 affected persons in 15 Negro families in Baltimore. Blood. 1963;21; 261-281.","DOI":"10.1182\/blood.V21.3.261.261"},{"key":"2020021222515440400_REF3","doi-asserted-by":"crossref","unstructured":"Pembrey ME, Wood WG, Weatherall DJ, Perrine RP. Fetal haemoglobin production and the sickle gene in the oases of Eastern Saudi Arabia. Br J Haematol.1978;40: 415-429.","DOI":"10.1111\/j.1365-2141.1978.tb05813.x"},{"key":"2020021222515440400_REF4","doi-asserted-by":"crossref","unstructured":"Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med.1995;332: 1317-1322.","DOI":"10.1056\/NEJM199505183322001"},{"key":"2020021222515440400_REF5","doi-asserted-by":"crossref","unstructured":"Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289: 1645-1651.","DOI":"10.1001\/jama.289.13.1645"},{"key":"2020021222515440400_REF6","doi-asserted-by":"crossref","unstructured":"Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood. 1997;89: 1078-1088.","DOI":"10.1182\/blood.V89.3.1078"},{"key":"2020021222515440400_REF7","doi-asserted-by":"crossref","unstructured":"van der Ploeg LH, Flavell RA. DNA methylation in the human gamma delta beta-globin locus in erythroid and nonerythroid tissues. Cell.1980;19: 947-958.","DOI":"10.1016\/0092-8674(80)90086-0"},{"key":"2020021222515440400_REF8","doi-asserted-by":"crossref","unstructured":"Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell.1980; 20: 85-93.","DOI":"10.1016\/0092-8674(80)90237-8"},{"key":"2020021222515440400_REF9","doi-asserted-by":"crossref","unstructured":"DeSimone J, Heller P, Hall L, Zwiers D. 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proc Natl Acad Sci U S A. 1982; 79: 4428-4431.","DOI":"10.1073\/pnas.79.14.4428"},{"key":"2020021222515440400_REF10","doi-asserted-by":"crossref","unstructured":"Ley TJ, DeSimone J, Noguchi CT, et al. 5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood. 1983;62: 370-380.","DOI":"10.1182\/blood.V62.2.370.bloodjournal622370"},{"key":"2020021222515440400_REF11","doi-asserted-by":"crossref","unstructured":"Lowrey CH, Nienhuis AW. Brief report: treatment with azacitidine of patients with end-stage betathalassemia. N Engl J Med.1993;329: 845-848.","DOI":"10.1056\/NEJM199309163291205"},{"key":"2020021222515440400_REF12","doi-asserted-by":"crossref","unstructured":"Charache S, Dover G, Smith K, Talbot CC Jr, Moyer M, Boyer S. Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta-globin gene complex. Proc Natl Acad Sci U S A. 1983;80: 4842-4846.","DOI":"10.1073\/pnas.80.15.4842"},{"key":"2020021222515440400_REF13","doi-asserted-by":"crossref","unstructured":"DeSimone J, Koshy M, Dorn L, et al. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood. 2002;99: 3905-3908.","DOI":"10.1182\/blood.V99.11.3905"},{"key":"2020021222515440400_REF14","doi-asserted-by":"crossref","unstructured":"Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med.1997;337: 762-769.","DOI":"10.1056\/NEJM199709113371107"},{"key":"2020021222515440400_REF15","doi-asserted-by":"crossref","unstructured":"Singer K, Chernoff AL, Singer L. Studies on abnormal hemoglobins, I: their demonstration in sickle cell anemia and other hematologic disorders by means of alkali denaturation. Blood. 1951;6: 413-428.","DOI":"10.1182\/blood.V6.5.413.413"},{"key":"2020021222515440400_REF16","doi-asserted-by":"crossref","unstructured":"Slayter HS. Secretion of thrombospondin from human blood platelets. Methods Enzymol.1989; 169: 251-268.","DOI":"10.1016\/0076-6879(89)69066-0"},{"key":"2020021222515440400_REF17","doi-asserted-by":"crossref","unstructured":"Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ. Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr.1996;128: 820-828.","DOI":"10.1016\/S0022-3476(96)70335-9"},{"key":"2020021222515440400_REF18","doi-asserted-by":"crossref","unstructured":"Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A. 1992;89: 1827-1831.","DOI":"10.1073\/pnas.89.5.1827"},{"key":"2020021222515440400_REF19","unstructured":"Eads CA, Laird PW. Combined bisulfite restriction analysis (COBRA). Methods Mol Biol.2002;200: 71-85."},{"key":"2020021222515440400_REF20","doi-asserted-by":"crossref","unstructured":"Tomer A, Harker LA, Kasey S, Eckman JR. Thrombogenesis in sickle cell disease. J Lab Clin Med.2001;137: 398-407.","DOI":"10.1067\/mlc.2001.115450"},{"key":"2020021222515440400_REF21","unstructured":"Francis RB Jr. Elevated fibrin D-dimer fragment in sickle cell anemia: evidence for activation of coagulation during the steady state as well as in painful crisis. Haemostasis. 1989;19: 105-111."},{"key":"2020021222515440400_REF22","unstructured":"Peters M, Plaat BE, ten Cate H, Wolters HJ, Weening RS, Brandjes DP. Enhanced thrombin generation in children with sickle cell disease. Thromb Haemost.1994;71: 169-172."},{"key":"2020021222515440400_REF23","doi-asserted-by":"crossref","unstructured":"Kaul DK, Fabry ME, Nagel RL. Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: pathophysiological implications. Proc Natl Acad Sci U S A. 1989;86: 3356-3360.","DOI":"10.1073\/pnas.86.9.3356"},{"key":"2020021222515440400_REF24","doi-asserted-by":"crossref","unstructured":"Akashi K, He X, Chen J, et al. Transcriptional accessibility for genes of multiple tissues and hematopoietic lineages is hierarchically controlled during early hematopoiesis. Blood. 2003;101: 383-389.","DOI":"10.1182\/blood-2002-06-1780"},{"key":"2020021222515440400_REF25","doi-asserted-by":"crossref","unstructured":"Visvader J, Adams JM. Megakaryocytic differentiation induced in 416B myeloid cells by GATA-2 and GATA-3 transgenes or 5-azacytidine is tightly coupled to GATA-1 expression. Blood. 1993;82: 1493-1501.","DOI":"10.1182\/blood.V82.5.1493.1493"},{"key":"2020021222515440400_REF26","doi-asserted-by":"crossref","unstructured":"Djalali M, Adolph S, Steinbach P, Winking H, Hameister H. Fragile sites induced by 5-azacytidine and 5-azadeoxycytidine in the murine genome. Hereditas. 1990;112: 77-81.","DOI":"10.1111\/j.1601-5223.1990.tb00140.x"},{"key":"2020021222515440400_REF27","doi-asserted-by":"crossref","unstructured":"McGregor DB, Brown AG, Cattanach P, et al. TFT and 6TG resistance of mouse lymphoma cells to analogs of azacytidine. Carcinogenesis. 1989;10: 2003-2008.","DOI":"10.1093\/carcin\/10.11.2003"},{"key":"2020021222515440400_REF28","unstructured":"Landolph JR, Jones PA. Mutagenicity of 5-azacytidine and related nucleosides in C3H\/10T 1\/2 clone 8 and V79 cells. Cancer Res.1982;42: 817-823."},{"key":"2020021222515440400_REF29","doi-asserted-by":"crossref","unstructured":"Laird PW, Jackson-Grusby L, Fazeli A, et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell.1995;81: 197-205.","DOI":"10.1016\/0092-8674(95)90329-1"},{"key":"2020021222515440400_REF30","doi-asserted-by":"crossref","unstructured":"Carr BI, Rahbar S, Asmeron Y, Riggs A, Winberg CD. Carcinogenicity and haemoglobin synthesis induction by cytidine analogues. Br J Cancer.1988;57: 395-402.","DOI":"10.1038\/bjc.1988.89"},{"key":"2020021222515440400_REF31","doi-asserted-by":"crossref","unstructured":"Lantry LE, Zhang Z, Crist KA, et al. 5-Aza-2\u2032-deoxycytidine is chemopreventive in a 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced primary mouse lung tumor model. Carcinogenesis. 1999;20: 343-346.","DOI":"10.1093\/carcin\/20.2.343"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/12\/3865\/1692116\/h82303003865.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/12\/3865\/1692116\/h82303003865.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T03:52:09Z","timestamp":1581565929000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/102\/12\/3865\/16711\/Effects-of-5aza2deoxycytidine-on-fetal-hemoglobin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12,1]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2003,12,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-05-1738","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12,1]]}}}